A REVIEW OF ADB-FUBINACA HORSE

values that believe increased efficacy than could be the case (i.e., the design may possibly treat the highest in the curve as being equivalent towards the nominal whole agonist). At the level of bias Examination (ΔΔlog RLength of Results: The period of ADB-BUTINACA’s outcomes will vary but is mostly described to get reasonably extended-Long la